<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Vaccinex Inc — News on 6ix</title>
    <link>https://6ix.com/company/vaccinex-inc</link>
    <description>Latest news and press releases for Vaccinex Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 23 Dec 2025 13:01:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/vaccinex-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d1e978dffbe2df11fe92.webp</url>
      <title>Vaccinex Inc</title>
      <link>https://6ix.com/company/vaccinex-inc</link>
    </image>
    <item>
      <title>Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease</title>
      <link>https://6ix.com/company/vaccinex-inc/news/vaccinex-inc-announces-dollar60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimers-disease</link>
      <guid isPermaLink="true">https://6ix.com/company/vaccinex-inc/news/vaccinex-inc-announces-dollar60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimers-disease</guid>
      <pubDate>Tue, 23 Dec 2025 13:01:00 GMT</pubDate>
      <description>ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatme</description>
    </item>
    <item>
      <title>Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease</title>
      <link>https://6ix.com/company/vaccinex-inc/news/vaccinex-inc-announces-dollar60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimers-disease-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vaccinex-inc/news/vaccinex-inc-announces-dollar60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimers-disease-1</guid>
      <pubDate>Tue, 23 Dec 2025 13:01:00 GMT</pubDate>
      <description>Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease.</description>
    </item>
    <item>
      <title>Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting</title>
      <link>https://6ix.com/company/vaccinex-inc/news/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/vaccinex-inc/news/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting</guid>
      <pubDate>Tue, 27 May 2025 12:45:00 GMT</pubDate>
      <description>Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhanc</description>
    </item>
    <item>
      <title>Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)</title>
      <link>https://6ix.com/company/vaccinex-inc/news/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemabs-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr</link>
      <guid isPermaLink="true">https://6ix.com/company/vaccinex-inc/news/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemabs-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr</guid>
      <pubDate>Mon, 21 Apr 2025 12:45:00 GMT</pubDate>
      <description>Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechn</description>
    </item>
    <item>
      <title>Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market</title>
      <link>https://6ix.com/company/vaccinex-inc/news/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market</link>
      <guid isPermaLink="true">https://6ix.com/company/vaccinex-inc/news/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market</guid>
      <pubDate>Fri, 07 Mar 2025 22:15:00 GMT</pubDate>
      <description>ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasd</description>
    </item>
  </channel>
</rss>